Key points are not available for this paper at this time.
Highlights•H. pylori γ-glutamyl transferase (GGT) depletes glutamine for up to 72 h in mice•PEG-GGT treatment increases infiltration of myeloid-derived suppressive cells in tumors•Across diverse cancers, TCGA analyses revealed glutamine depletion is not beneficialSummaryAlthough glutamine addiction in cancer cells is extensively reported, there is controversy on the impact of glutamine metabolism on the immune cells within the tumor microenvironment (TME). To address the role of extracellular glutamine, we enzymatically depleted circulating glutamine using PEGylated Helicobacter pylori gamma-glutamyl transferase (PEG-GGT) in syngeneic mouse models of breast and colon cancers. PEG-GGT treatment inhibits growth of cancer cells in vitro, but in vivo it increases myeloid-derived suppressor cells (MDSCs) and has no significant impact on tumor growth. By deriving a glutamine depletion signature, we analyze diverse human cancers within the TCGA and illustrate that glutamine depletion is not associated with favorable clinical outcomes and correlates with accumulation of MDSC. Broadly, our results help clarify the integrated impact of glutamine depletion within the TME and advance PEG-GGT as an enzymatic tool for the systemic and selective depletion (no asparaginase activity) of circulating glutamine in live animals.Graphical abstract
Kumar et al. (Fri,) studied this question.